Medicalgorithmics Sees Nearly 90% Growth in ECG Sessions in 2024
The Warsaw Stock Exchange-listed medtech company is consistently executing its growth strategy, aiming to achieve profitability and positive operating cash flow in the second half of the year. As part of this strategy, Medicalgorithmics focuses on offering leading software with AI-driven algorithms integrated with various ECG monitoring devices. Thanks to onboarding new clients and expanding in existing markets, the company recorded an 87.4% year-over-year increase in conducted tests in 2024, reaching over 270,000 sessions compared to 144,000 in 2023.